Pharma · Public company · Cambridge, MA, US
Alnylam Pharmaceuticals, Inc.
Ticker ALNY · SEC CIK 0001178670
Track this companyFree. Adds Alnylam Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2520 recruiting or active
Pipeline programs21From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline21
- NucresiranPhase 3 · Transthyretin Amyloidosis With CardiomyopathyClinicalTrials.gov · fetched Nov 12, 2026
- NucresiranPhase 3 · Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- PatisiranPhase 3 · Amyloidosis, HereditaryClinicalTrials.gov · fetched Nov 12, 2026
- PatisiranPhase 3 · Transthyretin Amyloidosis (ATTR) With CardiomyopathyClinicalTrials.gov · fetched Nov 12, 2026
- VutrisiranPhase 3 · Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- VutrisiranPhase 3 · Amyloidosis, HereditaryClinicalTrials.gov · fetched Nov 12, 2026
- VutrisiranPhase 3 · Transthyretin Amyloidosis (ATTR) With CardiomyopathyClinicalTrials.gov · fetched Nov 12, 2026
- ZilebesiranPhase 3 · High Risk Cardiovascular DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ALN-4324Phase 2 · Obese or Overweight Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- ALN-4324Phase 2 · Type 2 Diabetes Mellitus (T2DM)ClinicalTrials.gov · fetched Nov 12, 2026
- ALN-6400Phase 2 · Hereditary Hemorrhagic TelangiectasiaClinicalTrials.gov · fetched Nov 12, 2026
- ALN-6400Phase 2 · Von Willebrand Disease (VWD)ClinicalTrials.gov · fetched Nov 12, 2026
- ALN-AGT01Phase 2 · HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- ALN-AGT01 RVRPhase 2 · HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- ALN-APPPhase 2 · Cerebral Amyloid AngiopathyClinicalTrials.gov · fetched Nov 12, 2026
- MivelsiranPhase 2 · Down Syndrome-Associated Alzheimer's Disease (DS-AD)ClinicalTrials.gov · fetched Nov 12, 2026
- ZilebesiranPhase 2 · High Cardiovascular RiskClinicalTrials.gov · fetched Nov 12, 2026
- ZilebesiranPhase 2 · HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- ALN-APPPhase 1 · Early-Onset Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ALN-BCATPhase 1 · Advanced Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Advanced Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)PHASE2 · RECRUITING · started Aug 17, 2026ClinicalTrials.gov NCT07636811 · fetched Nov 12, 2026
- HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMBPHASE2 · RECRUITING · started Jul 30, 2026ClinicalTrials.gov NCT07575308 · fetched Nov 12, 2026
- A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With ZilebesiranPHASE2 · RECRUITING · started Apr 27, 2026ClinicalTrials.gov NCT07553442 · fetched Nov 12, 2026
- TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyPHASE3 · RECRUITING · started Feb 3, 2026ClinicalTrials.gov NCT07223203 · fetched Nov 12, 2026
- A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes MellitusPHASE2 · RECRUITING · started Jan 15, 2026ClinicalTrials.gov NCT07465224 · fetched Nov 12, 2026
- DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World SettingRECRUITING · started Jan 9, 2026ClinicalTrials.gov NCT07358078 · fetched Nov 12, 2026
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseasePHASE3 · RECRUITING · started Sep 6, 2025ClinicalTrials.gov NCT07181109 · fetched Nov 12, 2026
- TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPHASE3 · RECRUITING · started Jul 2, 2025ClinicalTrials.gov NCT07052903 · fetched Nov 12, 2026
- A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 3, 2025ClinicalTrials.gov NCT06845202 · fetched Nov 12, 2026
- A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaPHASE1 · RECRUITING · started Dec 30, 2024ClinicalTrials.gov NCT06600321 · fetched Nov 12, 2026
- A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPHASE3 · ENROLLING_BY_INVITATION · started Dec 3, 2024ClinicalTrials.gov NCT06679946 · fetched Nov 12, 2026
- A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 7, 2024ClinicalTrials.gov NCT06659640 · fetched Nov 12, 2026
- A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid AngiopathyPHASE2 · ACTIVE_NOT_RECRUITING · started May 17, 2024ClinicalTrials.gov NCT06393712 · fetched Nov 12, 2026
- Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)PHASE2 · COMPLETED · started Feb 29, 2024ClinicalTrials.gov NCT06272487 · fetched Nov 12, 2026
- Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran TherapyEARLY_PHASE1 · COMPLETED · started Aug 3, 2022ClinicalTrials.gov NCT05023889 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOADPHASE1 · RECRUITING · started Feb 4, 2022ClinicalTrials.gov NCT05231785 · fetched Nov 12, 2026
- BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)ACTIVE_NOT_RECRUITING · started Dec 13, 2021ClinicalTrials.gov NCT04982393 · fetched Nov 12, 2026
- A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate HypertensionPHASE2 · COMPLETED · started Jul 7, 2021ClinicalTrials.gov NCT04936035 · fetched Nov 12, 2026
- ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)RECRUITING · started Apr 26, 2021ClinicalTrials.gov NCT04883905 · fetched Nov 12, 2026
- ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)RECRUITING · started Nov 23, 2020ClinicalTrials.gov NCT04561518 · fetched Nov 12, 2026
- Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEFNA · RECRUITING · started Oct 2, 2020ClinicalTrials.gov NCT05577819 · fetched Nov 12, 2026
- Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance ProgramRECRUITING · started Aug 1, 2020ClinicalTrials.gov NCT05040373 · fetched Nov 12, 2026
- HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPHASE3 · ACTIVE_NOT_RECRUITING · started Nov 26, 2019ClinicalTrials.gov NCT04153149 · fetched Nov 12, 2026
- APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)PHASE3 · COMPLETED · started Sep 4, 2019ClinicalTrials.gov NCT03997383 · fetched Nov 12, 2026
- HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)PHASE3 · COMPLETED · started Feb 14, 2019ClinicalTrials.gov NCT03759379 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 27, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 4, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026